Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Shi

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
The American Journal of Gastroenterology|July 6, 2004
Tegaserod does not alter fasting or meal-induced biliary tract motilityRobert S Fisher, Johnson Thistle, Anthony Lembo, et al.
Journal of the American College of Cardiology|February 21, 2019
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEFMichael R Zile, Eileen O'Meara, Brian Claggett, et al.
European Journal of Heart Failure|April 3, 2014
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trialPardeep S Jhund, Brian Claggett, Milton Packer, et al.
Blood Pressure|July 7, 2007
Exceptional early blood pressure control rates: the ACCOMPLISH trialKenneth Jamerson, George L Bakris, Björn Dahlöf, et al.
JAMA Cardiology|November 15, 2016
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF TrialAkshay S Desai, Orly Vardeny, Brian Claggett, et al.
JACC. Heart Failure|January 10, 2016
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF TrialOrly Vardeny, Brian Claggett, Jacob A Udell, et al.
European Journal of Heart Failure|February 12, 2019
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
European Journal of Heart Failure|May 15, 2020
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Hypertension (Dallas, Tex. : 1979)|July 2, 2008
Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 yearsJoseph T Flynn, Kevin E C Meyers, Jose Pacheco Neto, et al.
European Journal of Heart Failure|June 11, 2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Milton Packer, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
The American Journal of Gastroenterology|July 6, 2004
Tegaserod does not alter fasting or meal-induced biliary tract motilityRobert S Fisher, Johnson Thistle, Anthony Lembo, et al.
Journal of the American College of Cardiology|February 21, 2019
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEFMichael R Zile, Eileen O'Meara, Brian Claggett, et al.
European Journal of Heart Failure|April 3, 2014
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trialPardeep S Jhund, Brian Claggett, Milton Packer, et al.
Blood Pressure|July 7, 2007
Exceptional early blood pressure control rates: the ACCOMPLISH trialKenneth Jamerson, George L Bakris, Björn Dahlöf, et al.
JAMA Cardiology|November 15, 2016
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF TrialAkshay S Desai, Orly Vardeny, Brian Claggett, et al.
JACC. Heart Failure|January 10, 2016
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF TrialOrly Vardeny, Brian Claggett, Jacob A Udell, et al.
European Journal of Heart Failure|February 12, 2019
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
European Journal of Heart Failure|May 15, 2020
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Hypertension (Dallas, Tex. : 1979)|July 2, 2008
Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 yearsJoseph T Flynn, Kevin E C Meyers, Jose Pacheco Neto, et al.
European Journal of Heart Failure|June 11, 2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Milton Packer, et al.
Pageof 7